Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

14 september 2026 uppdaterad av: InSilico Medicine Hong Kong Limited

A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.

The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).

In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Interventionell

Inskrivning (Beräknad)

320

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Anhui
      • Hefei, Anhui, Kina
        • Har inte rekryterat ännu
        • Anhui Provincial Hospital
      • Hefei, Anhui, Kina
        • Har inte rekryterat ännu
        • Anhui Chest Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina
        • Rekrytering
        • Peking Union Medical College Hospital
      • Beijing, Beijing Municipality, Kina
        • Rekrytering
        • Beijing Friendship hospital, Capital Medical University
      • Beijing, Beijing Municipality, Kina
        • Har inte rekryterat ännu
        • Beijing Chaoyang Hospital, Capital Medical University
    • Fujian
      • Fuzhou, Fujian, Kina
        • Har inte rekryterat ännu
        • Fuzhou University Affiliated Provincial Hospital
      • Xiamen, Fujian, Kina
        • Rekrytering
        • The Second Affiliated Hospital of Xiamen Medical College
    • Guangdong
      • Guangzhou, Guangdong, Kina
        • Rekrytering
        • The First Affiliated Hospital of Guangzhou Medical University
      • Guangzhou, Guangdong, Kina
        • Har inte rekryterat ännu
        • Nanfang Hospital, Southern Medical University
    • Guangxi
      • Nanning, Guangxi, Kina
        • Har inte rekryterat ännu
        • The First Affiliated Hospital of Guangxi Medical University
    • Hainan
      • Haikou, Hainan, Kina
        • Rekrytering
        • Hainan General Hospital
    • Hebei
      • Shijiazhuang, Hebei, Kina
        • Har inte rekryterat ännu
        • The Second Hospital of Hebei Medical University
      • Shijiazhuang, Hebei, Kina
        • Har inte rekryterat ännu
        • Hebei Medical University Third Hospital
    • Henan
      • Anyang, Henan, Kina
        • Rekrytering
        • The People's Hospital of Anyang City
      • Nanyang, Henan, Kina
        • Rekrytering
        • Nanyang First People's Hospital
      • Zhengzhou, Henan, Kina
        • Har inte rekryterat ännu
        • Henan Provincial People's Hospital
      • Zhengzhou, Henan, Kina
        • Har inte rekryterat ännu
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, Kina
        • Har inte rekryterat ännu
        • Renmin Hospital of Wuhan University
      • Wuhan, Hubei, Kina
        • Har inte rekryterat ännu
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Yichang, Hubei, Kina
        • Har inte rekryterat ännu
        • Yichang Central People's Hospital
    • Hunan
      • Changsha, Hunan, Kina
        • Har inte rekryterat ännu
        • The Second Xiangya Hospital of Central South University
      • Changsha, Hunan, Kina
        • Har inte rekryterat ännu
        • The Xiangya Hospital of Central South University
    • Inner Mongolia
      • Hohhot, Inner Mongolia, Kina
        • Har inte rekryterat ännu
        • The Affiliated Hospital of Inner Mongolia Medical University
    • Jiangsu
      • Nanjing, Jiangsu, Kina
        • Rekrytering
        • Nanjing Drum Tower Hospital
      • Xuzhou, Jiangsu, Kina
        • Har inte rekryterat ännu
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Kina
        • Har inte rekryterat ännu
        • Jiangxi Provincial People' Hospital
    • Jilin
      • Changchun, Jilin, Kina
        • Har inte rekryterat ännu
        • The Second Hospital of Jilin University
    • Liaoning
      • Shenyang, Liaoning, Kina
        • Har inte rekryterat ännu
        • Shengjing Hospital of China Medical University
    • Shaanxi
      • Xi'an, Shaanxi, Kina
        • Rekrytering
        • The Second Affiliated Hospital of Xi'an Jiaotong University
      • Xi'an, Shaanxi, Kina
        • Rekrytering
        • The First Affiliated Hospital of Xi'an Medical College
    • Shandong
      • Jinan, Shandong, Kina
        • Har inte rekryterat ännu
        • Qilu Hospital of Shandong University
      • Jinan, Shandong, Kina
        • Har inte rekryterat ännu
        • Introduction of the First Affiliated Hospital of Shandong First Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Rekrytering
        • Shanghai Pulmonary Hospital Affiliated to Tongji University
    • Shanxi
      • Taiyuan, Shanxi, Kina
        • Har inte rekryterat ännu
        • Shanxi Bethune Hospital
      • Yuncheng, Shanxi, Kina
        • Har inte rekryterat ännu
        • Yuncheng Central Hospital
    • Sichuan
      • Chengdu, Sichuan, Kina
        • Har inte rekryterat ännu
        • West China Hospital, Sichuan University
      • Chengdu, Sichuan, Kina
        • Har inte rekryterat ännu
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina
        • Har inte rekryterat ännu
        • Tianjin Medical University General Hospital
      • Tianjin, Tianjin Municipality, Kina
        • Har inte rekryterat ännu
        • Tianjin Chest Hospital
    • Xinjiang
      • Ürümqi, Xinjiang, Kina
        • Har inte rekryterat ännu
        • The First Affiliated Hospital of Xinjiang Medical University
    • Yunnan
      • Kunming, Yunnan, Kina
        • Har inte rekryterat ännu
        • The First People Hospital of Yunnan Province
    • Zhejiang
      • Hangzhou, Zhejiang, Kina
        • Har inte rekryterat ännu
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Hangzhou, Zhejiang, Kina
        • Rekrytering
        • Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
      • Jiaxing, Zhejiang, Kina
        • Har inte rekryterat ännu
        • The First Hospital of Jiaxing
      • Ningbo, Zhejiang, Kina
        • Har inte rekryterat ännu
        • Ningbo Medical Center Lihuili Hospital
      • Ningbo, Zhejiang, Kina
        • Har inte rekryterat ännu
        • The First Affiliated Hospital of Ningbo University
      • Wenzhou, Zhejiang, Kina
        • Har inte rekryterat ännu
        • The First Affiliated Hospital of Wenzhou Medical University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
  2. Patients aged ≥40 years at time of signing the ICF.
  3. Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
  4. UIP or probable UIP with fibrosis extent >10% at HRCT.
  5. Meet all the following criteria during the screening period:

    1. FVC ≥45% predicted of normal
    2. FEV1/FVC ≥0.7
    3. DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
  6. Background antifibrotic therapies are allowed, patients may be either:

    1. on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
    2. not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
  7. Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
  8. Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.

Exclusion criteria:

  1. Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
  2. Previous participation in a clinical study with rentosertib (active or placebo).
  3. Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
  4. Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
  5. Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
  6. Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
  7. Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
  8. Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
  9. Patients with Gilbert's disease
  10. Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
  11. Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
  12. Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
  13. Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
  14. Patient with a history of lung volume reduction surgery or lung transplant.
  15. Current smoker and/or cotinine (smoking) test positive.
  16. History of drug abuse, drug use, or alcohol abuse within the past 3 months.
  17. Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
  18. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
  19. Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
  20. Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
  21. Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
  22. Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study

    1. Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
    2. Medications associated with substantial risk for prolongation of corrected QT interval.
  23. Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
  24. Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
  25. Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
  26. Any condition that would interfere with the interpretation of study assessments or impair study participation.
  27. Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
Dosage form: Tablets; Frequency of administration: Orally QD. Other Names: Rentosertib
Placebo-jämförare: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
Dosage Form: Tablet; Frequency of administration: Orally QD.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
Tidsram: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
time to first occurrence of any disease progression
Tidsram: up to 52 weeks
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
up to 52 weeks
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
Tidsram: week 52
week 52
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
Tidsram: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
Tidsram: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
Tidsram: Weeks 0, 52
Weeks 0, 52

Andra resultatmått

Resultatmått
Tidsram
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
Tidsram: up to 56 weeks
up to 56 weeks
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
Tidsram: Weeks 0,2,4,8,12,26,39,52
Weeks 0,2,4,8,12,26,39,52
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
Tidsram: Weeks 0,2,4,8,12,26,39,52
Weeks 0,2,4,8,12,26,39,52
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
Tidsram: weeks 0, 12 ,26, and 52
weeks 0, 12 ,26, and 52
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
Tidsram: weeks 0, 52
weeks 0, 52
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
Tidsram: weeks 0, 52
weeks 0, 52

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 september 2026

Primärt slutförande (Beräknad)

30 oktober 2029

Avslutad studie (Beräknad)

30 oktober 2029

Studieregistreringsdatum

Först inskickad

22 juni 2026

Först inskickad som uppfyllde QC-kriterierna

1 juli 2026

Första postat (Faktisk)

7 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 september 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera